According to the lot release statistics of National Institutes for Food and Drug Control, in the first ten months of 2012, China’s total lot release volume of blood products was about 36.13 million bottles, an increase of 7.1% compared with the full year of 2011. In addition, except human coagulation factor VIII with a decreased lot release volume, other products saw growing release volume. In particular, human immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum albumin witnessed higher growth rates of 321%, 95%, 79%, 45% respectively in the first ten months of 2012. However, Chinese blood product enterprises have weak R&D capability, low plasma utilization and fewer product varieties. The domestic market is still dominated by technically undemanding human serum albumin and human immunoglobulin (ph4) for intravenous injection, which accounted for more than 60% of the lot release volume in 2012.

1. China Blood Product Industry Report, 2012-2015
Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma
stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the
implementation of favorable policies, widening gap between supply and demand, rising product prices and
other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2%
year on year.
From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or
obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical,
Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It’s
expected that China’s plasma supply tension will be further eased after 2013.
According to the lot release statistics of National Institutes for Food and Drug Control, in the first ten months
of 2012, China’s total lot release volume of blood products was about 36.13 million bottles, an increase
of 7.1% compared with the full year of 2011. In addition, except human coagulation factor VIII with a
decreased lot release volume, other products saw growing release volume. In particular, human
immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum albumin witnessed
higher growth rates of 321%, 95%, 79%, 45% respectively in the first ten months of 2012.
However, Chinese blood product enterprises have weak R&D capability, low plasma utilization and fewer
product varieties. The domestic market is still dominated by technically undemanding human serum albumin
and human immunoglobulin (ph4) for intravenous injection, which accounted for more than 60% of the lot
release volume in 2012.
In order to ease the domestic shortage of blood products, China has allowed the import of human serum
albumin and recombinant coagulation factor VIII in recent years. Human serum albumin imports have grown
rapidly due to low prices. The lot release volume was 8.51 million bottles in the first ten months of 2012,
occupying 47.5% of the lot release volume of such products (43.3% in 2011); Behring, Baxter, Instituto
Grifols and Octapharma were top four companies by lot release volume. However, due to high prices and
national policy restrictions, the import of recombinant coagulation factor VIII is very small, only Bayer and
Baxter products were allowed to be imported as of the end of 2012.
China Blood Product Industry Report, 2012-2015 covers the followings:
Plasma volume, plasma station distribution, market size and supply & demand of China blood product
industry; Competition pattern, policy environment and import & export of China blood product industry;
Market supply & demand and competition pattern of eight categories of blood products including human
serum albumin, human immunoglobulin (ph4) for intravenous injection, coagulation factors in China;
Development, operation, plasma stations and lot release volume of 12 local blood product producers in China.
As of the end of 2012, there were about 30 enterprises passing GMP certification and in normal operation,
among them, only Hualan Bio, Tiantan Biological Products (including Chengdu Ronsen), Shanghai RAAS,
Yuanda Shuyang Pharmaceutical, China Biologic Products have an annual plasma volume of over 300 tons. In
2012, the five enterprises accounted for 56.1% of China’s total plasma volume, and about 30% of
China’s blood product market revenue.
China Blood Product Industry Report, 2012-2015

2. Guangdong Shuanglin Bio-pharmacy, the sixth place holder, had nine plasma stations (three under
construction) in 2012, with a plasma volume of about 247 tons and blood product revenue of RMB 431
million. The company has held the largest lot release volume of rabies immunoglobulin in recent years.
Jiangxi Boya, though occupying a small market share (1.8% in 2012 by sales), has seven plasma stations, with
output and sales volume expected to be further enhanced in the future.
table Of Content
1. Profile Of Blood Products
1.1 Definition
1.2 Classification
1.3 Recombinant Blood Products
1.4 Industry Chain
1.5 Features
2. Overview Of China Blood Products Industry
2.1 Market Size
2.2 Development Status
2.3 Supply & Demand
2.3.1 Supply
2.3.2 Demand
2.4 Market Competition
2.5 Operating Environment
2.5.1 International Market
2.5.2 Policies
2.5.3 Domestic Biopharmaceutical Market
2.6 Import & Export
3. Blood Product Market Segments In China
3.1 Human Albumin
3.1.1 Supply & Demand
3.1.2 Competition Pattern
3.1.3 Prospects
3.2 Human Immunoglobulin (ph4) For Intravenous Injection
3.2.1 Supply & Demand
3.2.2 Competition Pattern
3.3 Coagulation Factor Viii
3.3.1 Supply & Demand
3.3.2 Competition Pattern
3.3.3 Prospects
China Blood Product Industry Report, 2012-2015

3. 3.4 Hepatitis B Immunoglobulin
3.4.1 Supply & Demand
3.4.2 Competition Pattern
3.5 Human Immunoglobulin
3.5.1 Supply & Demand
3.5.2 Competition Pattern
3.6 Human Prothrombin Complex
3.6.1 Supply & Demand
3.6.2 Competition Pattern
3.7 Tetanus Immunoglobulin
3.7.1 Supply & Demand
3.7.2 Competition Pattern
3.8 Rabies Immunoglobulin
3.8.1 Supply & Demand
3.8.2 Competition Pattern
4. Key Companies In China
4.1 China Biologic Products Inc.
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Clients And Suppliers
4.1.5 R&d And Investment
4.1.6 Shandong Taibang Biological Products Co., Ltd.
4.1.7 Guiyang Qianfeng Biological Products Co., Ltd.
4.1.8 Xi’an Hui Tian Blood Products Co., Ltd.
4.1.9 Development And Prospects
4.2 Hualan Biological Engineering Inc.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 Clients And Suppliers
4.2.6 R&d And Investment
4.2.7 Blood Products
4.2.8 Development And Prospects
4.3 Shanghai Raas Blood Products Co., Ltd.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 Clients And Suppliers
China Blood Product Industry Report, 2012-2015

4. 4.3.6 R&d And Investment
4.3.7 Development And Prospects
4.4 Beijing Tiantan Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Clients And Suppliers
4.4.5 Gross Margin
4.4.6 R&d And Investment
4.4.7 Blood Products (chengdu Ronsen Pharmaceutical Co., Ltd.)
4.4.8 Development And Prospects
4.5 Zhenxing Biopharmaceutical & Chemical Inc.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 Clients And Suppliers
4.5.6 R&d And Investment
4.5.7 Blood Products (guangdong Shuanglin Bio-pharmacy Co., Ltd.)
4.5.8 Development And Prospects
4.6 Jiangxi Boya Biopharmaceutical Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Clients And Suppliers
4.6.6 R&d And Investment
4.6.7 Development And Prospects
4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
4.7.1 Profile
4.7.2 Blood Products
4.8 Cnbg Shanghai Institute Of Biological Products
4.8.1 Profile
4.8.2 Blood Products
4.9 Shanxi Kangbao Biological Product Co., Ltd.
4.9.1 Profile
4.9.2 Blood Products
4.10 Green Cross
4.10.1 Profile
4.10.2 Blood Products
4.11 Humanwell Healthcare (group) Co., Ltd.
4.11.1 Profile
4.11.2 Operation
China Blood Product Industry Report, 2012-2015

5. 4.11.3 Blood Products (wuhan Zhongyuan Ruide Biological Products Co., Ltd.)
4.12 Walvax Biotechnology Co, Ltd.
4.12.1 Profile
4.12.2 Operation
4.12.3 Blood Products (hebei Daan Pharmaceutical Co., Ltd.)
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
China Blood Product Industry Report, 2012-2015